Physician profile
Mark Sapienza
NPI 1619929874
$7,939.71
in general payments reported to CMS, 2019-2025
36 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $150 · 2021: $729 · 2022: $1,721 · 2023: $1,393 · 2024: $954 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,983 · Education: $47.87 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.96 |
| Education | $47.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.78 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,201.65 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $996.52 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Celgene Corporation | $864.40 | 2019-2024 | Zeposia |
| Pfizer INC. | $476.39 | 2019-2025 | |
| Madrigal Pharmaceuticals | $441.52 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $238.47 | 2022 | |
| Janssen Scientific Affairs, LLC | $236.65 | 2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $197.59 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $162.56 | 2019-2022 | |
| Celltrion USA INC. | $153.11 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Olympus America INC. | $149.67 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $134.81 | 2020-2025 | Ocaliva |
| Daiichi Sankyo INC. | $109.72 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $93.75 | 2023-2024 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.80 | 2019-2025 | Entyvio, Gattex |
| Organon LLC | $76.00 | 2022-2023 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $73.92 | 2019-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $68.23 | 2019-2021 | |
| Ardelyx, INC. | $67.39 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $64.24 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $52.68 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $45.17 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $42.40 | 2022 | |
| Novo Nordisk INC | $34.03 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $26.56 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $25.19 | 2021 | |
| Sanofi US Services INC. | $20.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.34 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $15.99 | 2024 | Terlivaz |
| Capsovision, INC. | $14.64 | 2025 | Capsocam Plus |
| Fresenius Kabi USA, LLC | $13.39 | 2023 | |
| Endo Pharmaceuticals INC. | $13.38 | 2020 | |
| Ucb, INC. | $12.58 | 2019 | |
| Allergan, INC. | $11.70 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $8.49 | 2023 | Dilation (Need Marketed Name of Device(S), Eus Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sapienza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.